Protecting nerves from damage caused by chemotherapy
Neuroprotection for chemotherapy induced peripheral neuropathy
['FUNDING_R15'] · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · NIH-10876054
This study is looking at how a drug called Fluocinolone acetonide might help prevent painful nerve damage from chemotherapy, especially for those receiving a common treatment called Paclitaxel, so patients can feel better while getting their cancer care.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NORTH CAROLINA CHARLOTTE (nih funded) |
| Locations | 1 site (CHARLOTTE, UNITED STATES) |
| Trial ID | NIH-10876054 on ClinicalTrials.gov |
What this research studies
This research investigates how to prevent nerve damage caused by chemotherapy, specifically focusing on a common drug called Paclitaxel. Patients undergoing chemotherapy often experience painful side effects known as chemotherapy induced peripheral neuropathy (CIPN), which can lead to reduced treatment effectiveness. The study aims to identify a neuroprotective drug, Fluocinolone acetonide, that may help mitigate these painful symptoms. By using advanced imaging techniques, researchers will explore how this drug affects nerve cell function and health.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing chemotherapy for non-small cell lung cancer who are experiencing or at risk of developing peripheral neuropathy.
Not a fit: Patients who are not receiving chemotherapy or those with pre-existing neuropathy unrelated to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for cancer patients by reducing painful side effects of chemotherapy.
How similar studies have performed: While the approach of using Fluocinolone acetonide for this purpose is innovative, similar studies have shown promise in exploring neuroprotective strategies for chemotherapy-induced side effects.
Where this research is happening
CHARLOTTE, UNITED STATES
- UNIVERSITY OF NORTH CAROLINA CHARLOTTE — CHARLOTTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, IN HONG — UNIVERSITY OF NORTH CAROLINA CHARLOTTE
- Study coordinator: YANG, IN HONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: NSCLC - Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer